Vir shares tumble after apparent setback for COVID-19 drug

The National Institutes of Health has stopped enrollment into a clinical trial testing Vir Biotechnology's COVID-19 antibody drug in hospitalized patients after independent review "raised concerns about the magnitude of potential benefit," the company reported Wednesday. Shares in the California-based biotech tumbled 28%.